Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase i study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies Meeting Abstract
| Authors: | Richter, J.; Thomas, S. K.; Krishnan, A. Y.; Laubach, J. P.; Cohen, A. D.; Trudel, S.; Costa, L. J.; Bahlis, N. J.; Forsberg, P. A.; Kaedbey, R.; Fonseca, R.; Spencer, A.; Rodriguez-Otero, P.; Mateos, M. V.; Wong, C. H.; Cooper, J.; Tyagi, T.; Nakamura, R.; Choeurng, V.; Lesokhin, A. M. |
| Abstract Title: | Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase i study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 1021 |
| Language: | English |
| ACCESSION: | WOS:001412773700015 |
| DOI: | 10.1182/blood-2024-199542 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
